Insider Trading November 19, 2026 12:45 AM

CorMedix Director Myron Kaplan Discloses $122,000 Open-Market Share Purchase

The insider buy lands as CRMD trades near its 52-week low, following mixed third-quarter results and a revised price target from Oppenheimer.

By Ajmal Hussain
Share
Twitter Reddit Facebook LinkedIn
CRMD

CorMedix director Myron Kaplan acquired 25,000 shares of the company's common stock for approximately $122,000 on November 16, 2026, with prices ranging from $4.87 to $4.88. The purchase occurred while the stock was trading close to its 52-week low of $4.49 and had declined 7% over the prior week. Following the transaction, Kaplan directly holds 256,487 shares, with an additional 20,000 shares held indirectly by his spouse and 10,000 shares held by his spouse as guardian for grandchildren, for which he disclaims beneficial ownership. The company recently reported third-quarter revenue of $54.5 million, exceeding Wall Street expectations by 2.31%, but posted a wider-than-anticipated net loss of $0.19 per share versus analyst projections of a $0.10 loss, attributed to adjustments in the reimbursement setting for its main product, DefenCath. Oppenheimer lowered its price target from $15 to $13 while maintaining an Outperform rating, following the removal of TPN from its model and the inclusion of Heron, which adds commercial revenue and leverages existing infrastructure. The stock was recently trading at $4.50, down 3.64%.

CorMedix Director Myron Kaplan Discloses $122,000 Open-Market Share Purchase
CRMD
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • CorMedix director Myron Kaplan bought 25,000 shares for $122,000 on November 16, 2026, at prices between $4.87 and $4.88, with the stock near its 52-week low of $4.49.
  • The purchase followed third-quarter revenue of $54.5 million, which beat expectations by 2.31%, but a wider-than-anticipated net loss of $0.19 per share versus a projected $0.10 loss, attributed to reimbursement adjustments for DefenCath.
  • Oppenheimer lowered its price target to $13 from $15 while maintaining an Outperform rating, after removing TPN from its model and adding Heron, which contributes commercial revenue and leverages existing infrastructure.

CorMedix Inc. (NASDAQ:CRMD) director Myron Kaplan has disclosed an open-market purchase of 25,000 shares of the company's common stock, according to a regulatory filing. The transaction, executed on November 16, 2026, carried a total value of $122,000, with per-share prices ranging from $4.87 to $4.88.

The timing of the acquisition places the insider buy in close proximity to the stock's 52-week low of $4.49. Shares of CorMedix had declined 7% over the week leading up to the disclosure, a move that coincided with the director's purchase. The buy also comes as the stock was recently changing hands at $4.50, down 3.64% in the session.

Following the transaction, Kaplan directly holds 256,487 shares of CorMedix common stock. In addition to his direct stake, the filing indicates that 20,000 shares are held indirectly by his spouse, and a further 10,000 shares are held by his spouse as guardian for grandchildren. Kaplan disclaims beneficial ownership of these indirectly held securities.

Recent Financial Results

The insider transaction follows the company's third-quarter earnings report, which presented a mixed picture. CorMedix recorded revenue of $54.5 million, surpassing Wall Street expectations by 2.31%. However, the company reported a net loss of $0.19 per share, wider than the $0.10 loss analysts had projected. According to the report, the wider loss is attributed to adjustments in the reimbursement setting for its main product, DefenCath.

The revenue beat and the larger-than-expected loss illustrate the company's current financial landscape, where top-line performance exceeded consensus but bottom-line results were pressured by reimbursement-related factors tied to its primary product.

Analyst Adjustments

In a separate development, Oppenheimer has revised its valuation model for CorMedix, lowering its price target to $13 from $15 while maintaining an Outperform rating on the shares. The adjustment follows the removal of TPN from Oppenheimer's model and the inclusion of Heron, which adds commercial revenue and leverages existing infrastructure, according to the report.

The revised price target and the maintained Outperform rating reflect the analyst's updated view of the company's commercial outlook, incorporating the changes to the model. The report did not provide further detail on the specific assumptions behind the revision.

Valuation Context

According to InvestingPro analysis cited in the report, CRMD appears undervalued with a Fair Value of $6.71, placing it among undervalued stocks worth monitoring. The company trades at a P/E ratio of just 6.25 despite analyst expectations for continued profitability. The report did not elaborate on the methodology behind the Fair Value estimate or the specific basis for the profitability expectations.

The combination of an insider purchase near the 52-week low, a revenue beat with a wider net loss, and a lowered but still positive analyst price target presents a complex picture for investors evaluating the stock. The report did not indicate whether the director's purchase was part of a pre-arranged plan or discretionary, and it did not provide further context on the director's historical trading activity.

Risks

  • The wider-than-expected net loss of $0.19 per share, driven by reimbursement adjustments for DefenCath, raises uncertainty about the company's path to profitability and could pressure the stock if the trend continues.
  • The stock is trading near its 52-week low and has declined 7% over the past week, indicating negative market sentiment that may persist despite the insider purchase.
  • Oppenheimer's lowered price target and model changes, including the removal of TPN and addition of Heron, reflect revised assumptions that may not materialize as expected, leaving valuation uncertain.

More from Insider Trading

VSE Corp CEO John Cuomo Offloads $338,964 in Stock Under Pre-Arranged Plan Nov 19, 2026 Morningstar's Mansueto Offloads $1.8 Million in Shares Near 52-Week High Nov 19, 2026 Motorsport Games CFO Peter Hansen-Chambers Discloses $9,793 Share Purchase Nov 19, 2026 Peoples Bancorp Director Adds 200 Shares in Open-Market Purchase Nov 19, 2026 Atara Bio CEO Offloads $39,368 in Shares to Cover Tax Bill Nov 19, 2026